Similarly, studies have used protein expression assays, heme-binding affinity measurements, and in vivo murine models to validate the dual scavenging properties of the ApoHb–Hp complex, emphasizing its potential therapeutic application in conditions such as sickle cell disease and hemolytic uremic syndrome (41, 61). This evidence concerns the gene HP and hemolytic-uremic syndrome.